Abstract Ranibizumab (Lucentis®), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of ranibizumab were effective in the treatment of predominantly classic choroidal neovascularization (CNV) and minimally classic or occult CNV lesions. Ranibizumab has a well-established safety profile, and is associated with low rates of ocular and systemic serious adverse events. In head-to-head comparisons, the efficacy of monthly bevacizumab was equivalent to monthly ranibizumab at 1 and 2 years, individualized treatment with bevacizumab was equivalent to individualized treatment with ranibizumab at 1 and 2 years, and bimonthly aflibercept was noninferior to monthly ranibizumab at 1 year. These trials were not powered to detect between-treatment differences in safety.
clinical trials     0.9999999999886313^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Clinical_trial        

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

AMD                           0.9999686186380634^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

neovascular                   0.867968719931437^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/neovascularization    

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

vascular endothelial growth factor A1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor_A

Lucentis                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

age-related macular degeneration1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Macular_degeneration  

choroidal neovascularization  0.9999999986364401^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Choroidal_neovascularization

adverse events                0.9999411166561137^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Adverse_effect        

safety                        0.9999943704896601^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

CNV                           0.9999999999834017^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Copy-number_variation 

efficacy                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Efficacy              

lesions                       0.9999999997100986^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Lesion                

inhibitor                     0.978796925616436^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Enzyme_inhibitor      

AMD                           0.9999686186380634^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

ocular                        0.9999999999101874^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Human_eye             

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

CNV                           0.9999999999834017^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Copy-number_variation 

isoforms                      0.9998944911652643^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_isoform       

Ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

Ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

neovascular                   0.867968719931437^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/neovascularization    

occult                        0.9302717755904916^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Occult                

safety                        0.9999943704896601^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

